- NorthShield Uranium Royalties (TSX-V: NUR) raised $22M at $2.50/share, backed by Haywood Securities and Canaccord Genuity with a 12-month insider lockup.
- Luminate Diagnostics (CSE: LMDT) raised $12M at $1.00/share, deploying AI retinal imaging to detect Alzheimer’s and Parkinson’s markers in optometry clinics.
- NorthShield’s royalty model gives uranium commodity exposure with limited capital risk; spot uranium holds above US$85/lb (≈C$119/lb) in 2026.
- Luminate carries a shorter 6-month lockup expiring March 2027 and is pre-revenue, making it a higher-risk, earlier-stage play than NorthShield.
Two companies made their Canadian public-market debuts this week, collectively raising $34 million across the TSX Venture Exchange and the Canadian Securities Exchange. The listings span uranium royalties and AI-driven medical diagnostics — two sectors that have commanded outsized investor attention in 2026. Here’s what retail investors need to know before buying in.
NorthShield Uranium Royalties Corp. (TSX-V: NUR) — Raising $22M at $2.50/share
NorthShield Uranium Royalties Corp. began trading on the TSX Venture Exchange on September 22, 2026, priced at $2.50 per share and raising $22 million in its initial public offering. The Saskatoon-based company holds royalty interests on four uranium exploration and development properties in the Athabasca Basin — the world’s highest-grade uranium district, located in northern Saskatchewan. Rather than operating mines itself, NorthShield collects royalty streams as a percentage of revenue from operators, a model that limits capital exposure while maintaining commodity upside.
The royalty model is a familiar and well-regarded structure for Canadian resource investors. Companies like Franco-Nevada and Wheaton Precious Metals have demonstrated for gold and silver what NorthShield is attempting in uranium: steady, leverage-light returns tied to a commodity in structural supply deficit. Global uranium spot prices have held above US$85/lb (approximately C$119/lb at the current USD/CAD rate of 1.4044) for most of 2026, underpinned by nuclear energy’s resurgence as a low-carbon baseload power source in both Europe and Southeast Asia.
The offering was led by Haywood Securities and Canaccord Genuity as co-underwriters, with a syndicate that included PI Financial and Echelon Capital Markets. Institutional allocation is reported at approximately 60% of the raise, with the balance distributed through the retail brokerage network. Insider lockup is 12 months from the listing date, meaning founding shareholders and management cannot sell until September 22, 2027. The offering did not include a agents’ overallotment option, limiting the float to 8.8 million shares.
Luminate Diagnostics Inc. (CSE: LMDT) — Raising $12M at $1.00/share
Luminate Diagnostics Inc. listed on the Canadian Securities Exchange on September 23, 2026 at $1.00 per share, raising $12 million in a prospectus offering. The Vancouver-based company has developed an AI platform that analyzes retinal imaging scans to detect early markers of neurodegenerative diseases — including Alzheimer’s and Parkinson’s — before clinical symptoms emerge. The technology works with standard ophthalmological cameras already deployed in optometry clinics, meaning it requires no new hardware investment from healthcare providers.
Luminate’s commercial strategy targets Canadian optometry chains and provincial health networks as its initial distribution channel, with a U.S. FDA 510(k) submission planned for Q1 2027. The company has a pilot agreement in place with a national Canadian optometry group covering 140 clinic locations. Revenue is expected to be subscription-based, charged per scan analyzed — a SaaS-adjacent model that investors in health-tech have rewarded with premium multiples when adoption scales. The company reported no revenue in its most recent fiscal year and carries a deficit of $4.1 million as of June 30, 2026.
The deal was sole-bookrun by Ventum Capital Markets, with a 90-day greenshoe option on up to 1.8 million additional shares. Strategic backing includes participation from MedTech Ventures Canada, a Toronto-based healthcare-focused fund that took a 9.2% position. Insider lockup is 6 months, expiring March 23, 2027 — a shorter restriction period than NorthShield’s, which retail investors should weigh carefully. At $1.00, the entry price is accessible, but the pre-revenue status and shorter lockup introduce meaningful near-term volatility risk.
At a Glance: September 2026 New Listings
| Company | Ticker | Exchange | Sector | IPO Price | Funds Raised | Insider Lockup |
|---|---|---|---|---|---|---|
| NorthShield Uranium Royalties | NUR | TSX-V | Uranium / Royalties | $2.50 | $22M | 12 months |
| Luminate Diagnostics | LMDT | CSE | AI / MedTech | $1.00 | $12M | 6 months |
Investors considering either listing should review the full prospectus filed on SEDAR+ and assess their own risk tolerance. Early-stage listings on the TSX-V and CSE carry higher volatility and liquidity risk than established large-cap equities. Neither this article nor Boreal Markets constitutes investment advice.
